Literature DB >> 22373941

Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.

Olga Chernoloz1, Mostafa El Mansari, Pierre Blier.   

Abstract

Quetiapine is now used in the treatment of unipolar and bipolar disorders, both alone and in combination with other medications. In the current study, the sustained administration of quetiapine and N-Desalkyl quetiapine (NQuet) in rats in a 3 : 1 mixture (hQuetiapine (hQuet)) was used to mimic quetiapine exposure in patients because rats do not produce the latter important metabolite of quetiapine. Sustained administration of hQuet for 2 and 14 days, respectively, significantly enhanced the firing rate of norepinephrine (NE) neurons by blocking the cell body α₂-adrenergic autoreceptors on NE neurons, whether it was given alone or with a serotonin (5-HT) reuptake inhibitor. The 14-day regimen of hQuet enhanced the tonic activation of postsynaptic α₂- but not α₁-adrenergic receptors in the hippocampus. This increase in NE transmission was attributable to increased firing of NE neurons, the inhibition of NE reuptake by NQuet, and the attenuated function of terminal α₂-adrenergic receptors on NE terminals. Sustained administration of hQuet for 2 and 14 days, respectively, significantly inhibited the firing rate of 5-HT, whether it was given alone or with a 5-HT reuptake inhibitor, because of the blockade of excitatory α₁-adrenergic receptors on 5-HT neurons. Nevertheless, the 14-day regimen of hQuet enhanced the tonic activation of postsynaptic 5-HT(1A) receptors in the hippocampus. This increase in 5-HT transmission was attributable to the attenuated inhibitory function of the α₂-adrenergic receptors on 5-HT terminals and possibly to direct 5-HT(1A) receptor agonism by NQuet. The enhancement of NE and 5-HT transmission by hQuet may contribute to its antidepressant action in mood disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22373941      PMCID: PMC3358741          DOI: 10.1038/npp.2012.18

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  56 in total

1.  Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex.

Authors:  K Hatanaka; S Yatsugi; T Yamaguchi
Journal:  Eur J Pharmacol       Date:  2000-04-21       Impact factor: 4.432

2.  Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment.

Authors:  Stephen M Stahl
Journal:  CNS Spectr       Date:  2010-02       Impact factor: 3.790

3.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 4.  Use of atypical antipsychotics in refractory depression and anxiety.

Authors:  Charles B Nemeroff
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

5.  Effect of desipramine and amphetamine on noradrenergic neurotransmission: electrophysiological studies in the rat brain.

Authors:  O Curet; C De Montigny; P Blier
Journal:  Eur J Pharmacol       Date:  1992-10-06       Impact factor: 4.432

6.  Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.

Authors:  Andrew J Cutler; Stuart A Montgomery; David Feifel; Arthur Lazarus; Mikael Aström; Martin Brecher
Journal:  J Clin Psychiatry       Date:  2009-04-07       Impact factor: 4.384

7.  In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus.

Authors:  R Mongeau; P Blier; C de Montigny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

8.  Pharmacological characterization of presynaptic alpha-adrenoceptors modulating [3H]noradrenaline and [3H]5-hydroxytryptamine release from slices of the hippocampus of the rat.

Authors:  A L Frankhuyzen; A H Mulder
Journal:  Eur J Pharmacol       Date:  1982-06-16       Impact factor: 4.432

9.  Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons.

Authors:  Steven T Szabo; Pierre Blier
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial.

Authors:  Yves Chaput; Annick Magnan; Alain Gendron
Journal:  BMC Psychiatry       Date:  2008-08-28       Impact factor: 3.630

View more
  8 in total

1.  Physiologically relevant changes in serotonin resolved by fast microdialysis.

Authors:  Hongyan Yang; Andrew B Thompson; Bryan J McIntosh; Stefanie C Altieri; Anne M Andrews
Journal:  ACS Chem Neurosci       Date:  2013-04-24       Impact factor: 4.418

2.  Acute and chronic treatment with quetiapine induces antidepressant-like behavior and exerts antioxidant effects in the rat brain.

Authors:  Zuleide M Ignácio; Gislaine Z Réus; Helena M Abelaira; Airam B de Moura; Thays G de Souza; Danyela Matos; Mariana P Goldim; Khiany Mathias; Leandro Garbossa; Fabricia Petronilho; João Quevedo
Journal:  Metab Brain Dis       Date:  2017-05-06       Impact factor: 3.584

Review 3.  Serotonin and beyond: therapeutics for major depression.

Authors:  Pierre Blier; Mostafa El Mansari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

Review 4.  A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.

Authors:  Jeremy D Coplan; Srinath Gopinath; Chadi G Abdallah; Benjamin R Berry
Journal:  Front Behav Neurosci       Date:  2014-05-20       Impact factor: 3.558

5.  Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group.

Authors:  Kurt-Wolfram Sühs; Christoph Correll; Christian K Eberlein; Refik Pul; Helge Frieling; Stefan Bleich; Kai G Kahl
Journal:  Brain Behav       Date:  2015-02-19       Impact factor: 2.708

6.  Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study.

Authors:  Chris A Oosterhof; Mostafa El Mansari; Christoffer Bundgaard; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2015-10-01       Impact factor: 5.176

Review 7.  Divergent effects of acute and repeated quetiapine treatment on dopamine neuron activity in normal vs. chronic mild stress induced hypodopaminergic states.

Authors:  Jared L Moreines; Zoe L Owrutsky; Kimberly G Gagnon; Anthony A Grace
Journal:  Transl Psychiatry       Date:  2017-12-11       Impact factor: 6.222

Review 8.  Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders.

Authors:  Daniil Grinchii; Eliyahu Dremencov
Journal:  Int J Mol Sci       Date:  2020-12-15       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.